MC

543.5

-5.36%↓

SANES

6.042

-5%↓

BNP

73.98

-4.74%↓

CS.FR

39.63

-1.74%↓

ALV

353.7

-0.79%↓

MC

543.5

-5.36%↓

SANES

6.042

-5%↓

BNP

73.98

-4.74%↓

CS.FR

39.63

-1.74%↓

ALV

353.7

-0.79%↓

MC

543.5

-5.36%↓

SANES

6.042

-5%↓

BNP

73.98

-4.74%↓

CS.FR

39.63

-1.74%↓

ALV

353.7

-0.79%↓

MC

543.5

-5.36%↓

SANES

6.042

-5%↓

BNP

73.98

-4.74%↓

CS.FR

39.63

-1.74%↓

ALV

353.7

-0.79%↓

MC

543.5

-5.36%↓

SANES

6.042

-5%↓

BNP

73.98

-4.74%↓

CS.FR

39.63

-1.74%↓

ALV

353.7

-0.79%↓

Search

Grifols SA

Gesloten

SectorFinanciën

8.408 0.17

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

8.344

Max

8.704

Belangrijke statistieken

By Trading Economics

Inkomsten

17M

69M

Verkoop

183M

2B

K/W

Sectorgemiddelde

45.229

22.015

EPS

0.101

Winstmarge

3.491

Werknemers

23,833

EBITDA

57M

482M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+72.24% upside

Marktinformatie

By TradingEconomics

Marktkapitalisatie

3.3B

6.8B

Vorige openingsprijs

8.24

Vorige sluitingsprijs

8.408

Nieuwssentiment

By Acuity

65%

35%

484 / 542 Rangschikking in Finance

Technische score

By Trading Central

Vertrouwen

Neutral Evidence

Grifols SA Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

2 apr 2025, 17:19 UTC

Acquisities, Fusies, Overnames

Grifols in 'Very Preliminary Talks' With Brookfield Over Renewed Takeover Bid -- 2nd Update

2 apr 2025, 13:02 UTC

Acquisities, Fusies, Overnames

Grifols, Brookfield Deny Takeover Talks After Report of Renewed Interest -- Update

2 apr 2025, 10:13 UTC

Acquisities, Fusies, Overnames

Grifols Board Denies Media Reports Over Talks With Brookfield for Another Takeover Bid

8 jul 2024, 10:40 UTC

Acquisities, Fusies, Overnames

Trending: Grifols Founding Family, Brookfield Eye Takeover Bid for Spanish Drugmaker

8 jul 2024, 09:13 UTC

Acquisities, Fusies, Overnames

Grifols Faces Delisting Bid From Founding Family and Brookfield

2 apr 2025, 09:27 UTC

Populaire aandelen

Stocks to Watch Wednesday: Tesla, Newsmax, Novo Nordisk -- WSJ

Peer Vergelijking

Prijswijziging

Grifols SA Prognose

Koersdoel

By TipRanks

72.24% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 14.02 EUR  72.24%

Hoogste 19.05 EUR

Laagste 11 EUR

Gebaseerd op 3 Wall Street-analisten die 12-maands prijsdoelen bieden voor Grifols SA - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

3 ratings

2

Buy

1

Hold

0

Sell

Technische score

By Trading Central

8.152 / 8.574Steun & Weerstand

Korte Termijn

Neutral Evidence

Gemiddeld Termijn

Weak Bearish Evidence

Lange Termijn

Bearish Evidence

Sentiment

By Acuity

484 / 542 Rangschikking in Financiën

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Grifols SA

Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease. It markets diagnostic testing equipment, reagents, and other equipment; biological products; manufactures and sells plasma to third parties; and involves in research activities, as well as markets pharmaceutical products for hospital pharmacies. In addition, the company offers Yimmugo PID, an immunology drug; and Yimmugo ITP, a hematology drug. Further, it develops Xembify Pre-filled syringes, FlexBag, and Prolastin vials; Xembify Biweekly dosing, Prolastin-C, Fostamatinib2, and VISTASEAL which are in Phase IV development stage; Xembify, Albumin 20% and 5%, Fibrinogen, Trimodulin, Cytotec pregnancy, and AMBAR-Next in Phase III development stage; and AKST4290 that is in Phase II clinical development. Additionally, it offers recIG, Alpha-1 AT in non-cystic fibrosis bronchiectasis, ATIII, GIGA 2339, GIGA564, and OSIG. It has collaboration agreements with Canadian Blood Services for the processing of other plasma-derived products and with GIANT; and GigaGen to develop recombinant polyclonal immunoglobulin therapies. The company was founded in 1909 and is headquartered in Barcelona, Spain.